Stocks and Investing
Stocks and Investing
Fri, July 29, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gil Blum Maintained (SRPT) at Strong Buy with Increased Target to $162 on, Jul 29th, 2022
Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $150 to $162 on, Jul 29th, 2022.
Gil has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Gil's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $80 on, Friday, July 15th, 2022
- Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $90 on, Friday, June 24th, 2022
These are the ratings of the 2 analyists that currently disagree with Gil
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
Contributing Sources